
Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.

Your AI-Trained Oncology Knowledge Connection!


Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.

Intermittent degarelix administered as described is noninferior to continuous androgen deprivation in maintaining PSA suppression, which indicates that degarelix is a suitable treatment option in men being considered for intermittent androgen ablation.

Published: May 8th 2020 | Updated:

Published: January 3rd 2016 | Updated: